QuidelOrtho Looks Mispriced If 2026's FCF Turnaround Materializes

The key takeaway is not that QDEL is deteriorating uniformly, but that management is actively shrinking lower-quality revenue while the mix shifts toward more durable, recurring lab and blood-bank demand. That usually improves gross margin stability and multiple support even if reported top-line growth looks choppy, because investors tend to pay up for revenue visibility rather than headline growth alone. In other words, the market may be over-penalizing the company for deliberate pruning of businesses with weaker strategic value.

The beneficiaries are likely competitors in point-of-care and donor-screening niches that can absorb lost share, but the second-order effect is more important: QDEL’s remaining core businesses become easier to underwrite if the exit is truly complete within the next 1-2 quarters. That can also reduce inventory and working-capital drag, which matters for a name where cash conversion is often the real debate. If Labs is now the dominant engine, the stock should trade more like a steadier diagnostics platform than a COVID hangover story.

The contrarian risk is that investors may be anchoring on segment weakness without separating structural decline from intentional portfolio cleanup. If Labs and Immunohematology continue to expand over the next 2-3 quarters, the market could re-rate the name on mix improvement before absolute revenue growth fully normalizes. Conversely, if post-exit growth in the remaining portfolio stalls, the market will conclude this is not a pruning story but a shrinking one, and the de-rating could continue for another 6-12 months.